LACTB and cancer: In contrast to the decreasing trends of overall antibiotic consumption rates in cancer decedents at different timespans before death, beta-lactam/beta-lactamase inhibitor combinations, carbapenems, and polymyxins were used most during the last month of life (Figure 2, Supplementary Figure 7, and Supplementary Table 1).